Introduction
Enteric bacterial pathogens constitute a major burden on global health, especially 74 in children younger than five years of age [1, 2] . The Global Enteric Multicenter Study 75 (GEMS) surveyed children ages 0-59 months in seven countries in sub-Saharan Africa 76 and south Asia and identified the leading etiological agents of moderate-to-severe 77 (MSD) and less-severe diarrhea (LSD) in this age group [1, 3] . Included on the list were 78 Shigella species, Campylobacter jejuni, Vibrio cholerae and enterotoxigenic E. coli 79 (ETEC) among others. Episodes of MSD and LSD can each have long term impacts on 80 child health, most notably linear growth faltering. Other pathogens like multidrug 81 resistant typhoid and invasive non-typhoidal Salmonella (iNTS) caused by different 82 serovars of Salmonella enterica are also a source of infections in sub-Saharan Africa 83 that can have short-and long-term health consequences [4] [5] [6] . The dire need for 84 vaccines against enteric bacterial pathogens like C. jejuni, Shigella, ETEC and 85 Salmonella has been recognized for decades, especially within military settings [2] . 86 While there are numerous candidate vaccines under evaluation, the path forward 87 remains challenging and alternative approaches need to be considered to combat C. 88 jejuni, Shigella, ETEC and Salmonella in the immediate future. 89 With the advent of affordable and scalable platforms for the production of 90 pathogen-specific IgG and secretory IgA (SIgA), the notion of oral passive immunization 91 with polyclonal or monoclonal antibodies (mAbs) as a strategy to blunt diarrheal 92 diseases in high-risk populations is gaining attention. For example, it was reported that 93 ingestion of polyclonal hyperimmune bovine colostrum (HBC), marketed as Travelan Ò , 94 reduces experimental traveler's associated ETEC infection [7] . Sears and colleagues 95 recently presented evidence that IgG and possibly IgA antibodies in Travelan Ò and a 96 related HBC product (IMM-24E) may exert their protective effects through arresting 97 ETEC motility and complement-mediated killing [8] . More recently, Guintini and 98 colleagues demonstrated that oral administration of IgG or IgA mAbs targeting a single 99 adhesin (CfaE) were able to reduce ETEC colonization by several orders of magnitude 100 in a mouse model [9] . In the case of invasive Salmonella enterica serovar Typhimurium 101 (STm), Corthésy and colleagues reported that polyreactive secretory-like IgA/IgM 102 mixtures were capable of reducing bacterial entry into Peyer's patch tissues [10, 11] .
While these studies represent a proof of concept that oral immunoglobulins can 104 abrogate Salmonella infection, the amount of IgA/IgM required to achieve a reduction in 105 bacterial burden was excessive (i.e., ~10 mg of SIgA/IgM; ~ 500 mg/kg) and likely 106 impractical if translated to a human setting. For that reason, we sought to investigate 107 the potential benefit of a mAb-based passive immunization approach in blocking 108 invasive Salmonella. 109 Sal4 is a well-characterized, dimeric IgA mAb originally isolated from a panel of B 110 cell hybridomas derived from Peyer's patch tissues of mice that had been immunized 111 with an attenuated strain of STm [12] . Sal4 recognizes the O5-antigen of STm 112 lipopolysaccharide (LPS) [13] . The O-antigen of STm is a tetrasaccharide consisting of 113 galactose, rhamnose, and mannose, with an abequose (3,6 dideoy-galactose) moiety 114 on the mannose side chain. The O5 antigen is conferred when the abequose residue is 115 acetylated, while the O4 antigen is defined by the absence of acetylation modification 116 [14] . Both STm O4 and O5 serotypes are invasive in mouse models of intragastric and 117 parenteral challenge, although the actual lethal dose values may vary slightly [15] . 118 In the so-called backpack tumor model (described elsewhere in this manuscript), 119 it was shown that Sal4 IgA, when actively transported into the intestinal lumen of mice in 120 form of secretory IgA (SIgA), was able to reduce STm uptake into Peyer's patch tissues 121 [15]. Peyer's patches represent the point of entry for invasive strains of Salmonella 122 enterica and the bottleneck for systemic dissemination [16] . Sal4 IgA's protective 123 capacity was limited to the gut, as even high levels of Sal4 IgA in circulation were 124 unable to curtail STm systemic infection in the face of a parenteral bacterial challenge 125 6 and even IgG. We also generated and characterized an second O5-specific IgA mAb 135 and compared it to Sal4 IgA in vitro and in vivo.
137

Methods
138
Bacterial strains and growth conditions. Salmonella enterica serovar Typhimurium 139 (STm) strains used in this study are described in Table 1 IgA resulted in a dose-dependent reduction in the number of AR05 recovered in Peyer's 302 patch tissues (Fig 1) . The highest dose of Sal4 IgA tested (12 µg) resulted in >4 log10 303 reduction in AR05 invasion efficiency, as compared to controls. The absolute number of 304 AR04 recovered from the same Peyer's patch tissues was unaffected by Sal4 IgA. The 305 relative impact of Sal4 IgA on Peyer's patch invasion was more apparent when the 306 recovery values were expressed as a CI (Fig 1) . By this metric, the addition of as little 307 as 0.4 µg of Sal4 IgA rendered AR05 at a competitive disadvantage compared to AR04 (Fig 1) . The addition of greater amounts of Sal4 further reduced the CI with a maximal 309 reduction occurring at concentrations above 1.2 µg Sal4 IgA. Invasion of Peyer's patch 310 tissues by AR05 and AR04 was unaffected by 2D6, an anti-Vibrio cholerae IgA mAb 311 that served as the isotype control for these studies [15, 22] . effective at limiting uptake of AR05 into Peyer's patches (Fig 3A) , indicating that the 353 addition of SC did not enhance the protective capacity of Sal4 dIgA in this model. We postulated that the advantage of SC may only be apparent when antibody 366 interacts with the intestinal environment in advance of bacterial challenge. We therefore 367 repeated the experiments in which Sal4 dIgA and SIgA were given to mice by gavage 368 immediately before STm challenge. Once again, however, Sal4 SIgA was no more 369 effective than Sal4 dIgA at reducing invasion of AR05 into Peyer's patch tissues. We conclude that, at least in this model of passive oral immunization, the potency of Sal4 371 IgA is not enhanced by the addition of SC (Fig 3B) . 372 
Contribution of IgA avidity in inhibiting STm invasion of epithelial cells in 373
vitro and Peyer's patch tissues in vivo. While antibody avidity has been cited as an 374 important parameter in controlling Salmonella infection in the gut following vaccination 375 [27], its significance in the context passive oral immunization has not been examined. 376 For instance, Sal4 IgA is the only O5-specific mAb that has been comprehensively 377 characterized for biological activity in vitro and in vivo [12, 14, 15, 17, 19, 28] . We are 378 unaware of experiments in the literature that have directly compared anti-STm IgA 379 mAbs of differing avidities but with similar (or identical) epitope specificities. 380 We therefore sought to generate additional O5-specific mouse IgA mAbs and 393 We next examined PeA3 IgA for the ability able to block Salmonella 394 pathogenicity island 1 (SPI-1) type III secretion system (T3SS)-mediated entry of STm 395 into HeLa cells [17] . A 1:1 mixture of AR05 and AR04 was treated with PeA3, Sal4, or 396 the isotype control, 2D6, before being applied to HeLa cells with gentle centrifugation to 397 bypass the need for motility in the invasion assay [17] . At the dose of antibody tested, 398 PeA3 IgA treatment resulted in a significant reduction in AR05 invasion of HeLa cells, 399 although its efficacy was slightly less than that of Sal4 IgA (Fig 4) . (Fig 4) . However, at the low dose, Sal4 IgA was superior to 419 PeA3, as evidenced by mean CI values of 0.16 (± 0.30) versus 0.64 (± 0.20), 420 respectively (Fig 4) . Thus, the relative avidities of Sal4 and PeA3 for STm in vitro 421 mirrors their efficacy in vivo.
422
Potential of Sal4 IgG to function in passive immunization by the oral route. 423 In clinical trials, ingestion of bovine milk-or colostrum-derived immunoglobulins 424 consisting mainly of IgG from immunized dairy cows is sufficient to significantly reduce 425 ETEC infection in adult volunteers [7, 29], indicating a role for IgG in passive oral 426 immunizations. In fact, in a recent report, orally delivered anti-colonization factor antigen 427 CFA/I IgG and SIgA human mAbs were equally effective at blocking ETEC infection in a 428 mouse model [9] . 429 To investigate the potential of orally administered IgG to prevent STm invasion of agglutination of STm in liquid culture, though slightly less effectively than Sal4 IgA (i.e. 436 more antibody and longer incubation time was required to achieve macroagglutination). 437 In a soft agar motility assay, Sal4 IgG limited bacterial spread over the course of the 6 h 438 experiment, although slightly less effectively than Sal4 IgA. In the HeLa cell invasion 439 assay, Sal4 IgG and Sal4 IgA were more or less equivalent in their abilities to block 440 AR05 uptake (Fig 5) . We therefore conclude that the Sal4 IgG1 molecule has expected 441 the biological activities associated with Sal4 IgA, at least in vitro. (Fig 6) . In contrast, Sal4 IgG1 had no effect on STm invasion, as 474 evidenced by a CI value of 0.95 ± 0.13 (Fig 6) . The failure of Sal4 IgG1 to function in 475 these studies could not be overcome by increasing antibody dose (e.g., >750 µg) or Table) . Upon the addition of pepsin, however, IgG1 declined so 495 precipitously that it was undetectable at 10 min. At the same time point (10 min), Sal4 496 IgA had declined to just ~10% of starting levels, but then remained detectable until 30 497 min. Collectively, these results confirmed the differential sensitivity of Sal4 IgG1 and IgA 498 to the gastric environment. 499 The in vitro stability studies with Sal4 IgG prompted us to repeat the passive 500 immunization studies with the addition of sodium bicarbonate plus protease inhibitors. 501 Specifically, Sal4 IgG1 in sodium bicarbonate (3% NaHCO3) plus protease inhibitors 502 administered to mice by gavage 1 min or 20 min prior STm challenge. Under these 503 conditions, Sal4 IgG1 did in fact block STm invasion into Peyer's patch tissues, but only 504 when given immediately before STm challenge (Fig 6) . Collectively, these results 505 suggest that ineffectiveness of Sal4 IgG1, as compared to Sal4 IgA, is due to its 506 instability in the gut environment. In this study, we investigated the potential of orally administered mAbs to passively 510 immunize mice against invasive Salmonella. The study was motivated by several 511 factors. First is the rapid emergence of multi-drug resistance Salmonella infections, 512 which constitute an increasing threat to public health in developing and even developed 513 countries [30, 31] . Second, given the difficulty and extended timeline associated with the 514 vaccine development, there is pressure from federal and private foundations to explore 515 alternative strategies as a means of protecting at risk individuals from debilitating enteric 516 infections. With the remarkable advances in recombinant mAb engineering and scale-up 517 using mammalian cells, transgenic animals, plants and even seed-based [32] 518 production platforms, the prospect of combatting diarrheal diseases through orally 519 administered mAb cocktails is technically feasible and cost-effective. 520 We found that direct administration of Sal4 IgA to adult mice by gavage 521 overcomes many of the impediments associated with the so-called "backpack" tumor protease-mediated degradation [21, 40, 41] . It is unclear if the physiologic distribution 558 of SIgA is recapitulated when antibody is administered by gavage. Our attempts to 559 track, using immunohistochemistry, Sal4 SIgA in the small intestine following oral 560 delivery have not been successful to date. Another possible explanation for why SC did 561 not impart a benefit to Sal4 IgA is that the rate-limiting determinant for antibody-562 mediated protection in this model is dilution effects upon gavage, not protease 563 sensitivity or mucus anchoring, where SC would be expected to play an important role. 564 The comparison between PeA3 and Sal4 IgA mAbs in the mouse model of clearly advantageous since much lower doses would be required to achieve protection. 576 Indeed, in the case of respiratory infections, the selection for higher affinity mAbs 577 resulted in correspondingly higher neutralizing activities and in vivo potency [42] . 578 It was disappointing (albeit not surprising) to discover that an IgG1 variant of Sal4 579 had a marginal capacity (and only when given with protease inhibitors and sodium 580 bicarbonate) to passively immunize mice against intragastric Salmonella infection. 581 Indeed, our results are consistent with other reports that demonstrate IgG1 instability in 582 the gastric environment is a major contributor to its failure to function in the gut against 583 Salmonella and other pathogens. It is likely that the heavily glycosylated nature of IgA 584 provides an advantage upon direct delivery into the gut [43, 44] in terms of maintaining 585 both direct antigen binding and crosslinking between multiple antigens [40], while the 586 IgG mAb, with a lone pair of N-glycans on the Fc region [45], is outmatched. Other factors may also be at play. Sal4 IgG1, which is a monomer, likely differs from Sal4 IgA, 588 which is a dimer, in its ability to promote bacterial agglutination. We cannot rule out the 589 possibility that the nature of agglutination between IgG and IgA is quantitatively different 590 considering that we did observe slight differences in the kinetics of microagglutination 591 between to two antibody isotypes. 
